Capital Flow Monitor · Sponsors · CIK 1662774
Quince Therapeutics, Inc.
611 Gateway Blvd., Suite 273, South San Francisco, CA, 94080 · 415-910-5717
Biotechnology · Corporation· inc. CALIFORNIA true
Fit score
—
Offering
$186.4M
Sold
$114.7M
% sold
61.5%
Investors
27
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2026-06-11 | D | 506(b) | $7.4M | $0 | 0.0% | 66 | EDGAR ↗ |
| 2026-06-11 | D ·current | 506(b) | $186.4M | $114.7M | 61.5% | 27 | EDGAR ↗ |
| 2025-07-01 | D | 506(b) | $21.9M | $11.5M | 52.5% | 15 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed.
- Dirk Thye — Executive Officer / Director, South San Francisco, CA
- Brigette Roberts — Executive Officer / Director, South San Francisco, CA
- Charles Ryan — Executive Officer, South San Francisco, CA
- Brendan Hannah — Executive Officer, South San Francisco, CA
- David Lamond — Director, South San Francisco, CA
- Christopher Senner — Director, South San Francisco, CA
- June Bray — Director, South San Francisco, CA
Placement agents
- Lifesci Capital · 0 RE raises
- Citizens Jmp Securities, Llc · 0 RE raises
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.